You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023232020
Dec 202358012
Jan 20246304
Feb 20243208
Mar 20244405
Apr 20242403
May 20245008
Jun 202440017
Jul 20243808
Aug 202456014
Sep 202476019
Oct 20244006
Nov 202478014
Dec 202438020
Jan 202563016
Feb 20256011
Mar 2025008
Apr 2025001
May 2025005
Jun 2025002
Total9380201